Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 18/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12971082 | 0.92 | MAPK1 (0.60) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12970798 | 0.91 | MAPK1 (0.57) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12971054 | 0.91 | MAPK1 (0.57) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12979278 | 0.90 | MAPK1 (0.55) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12970910 | 0.89 | MAPK1 (0.56) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12970942 | 0.88 | MAPK1 (0.54) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12971026 | 0.87 | MAPK1 (0.53) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12970927 | 0.86 | MAPK1 (0.65) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12971133 | 0.86 | MAPK1 (0.59) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12971156 | 0.86 | MAPK1 (0.58) | MAPK1PIK3CAMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694068-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | Æterna Zentaris GmbH (DE) | 2014-02-12 | — | — | EP | claimed |
| WO-2012136694-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ÆTERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | WO | claimed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | claimed |
| EP-2508184-A1 | Pyridopyrazine derivatives and their use | Æterna Zentaris GmbH (DE) | 2012-10-10 | — | — | EP | claimed |
| US-8912189-B2 | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912189-B2 | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912189-B2 | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| EP-2694068-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | Æterna Zentaris GmbH (DE) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012136694-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ÆTERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012136694-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ÆTERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| EP-2508184-A1 | Pyridopyrazine derivatives and their use | Æterna Zentaris GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-2508184-A1 | Pyridopyrazine derivatives and their use | Æterna Zentaris GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | MAPK1 58/4885PIK3CA 866/4885MAPK8 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.